Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.9779 USD | +2.93% | +0.81% | +91.37% |
Apr. 19 | YS Biopharma Co., Ltd. Reports Earnings Results for the Nine Months Ended December 31, 2023 | CI |
Apr. 18 | YS Biopharma Receives Clinical Trial Approval for Potential Hepatitis B Treatment | MT |
Sales 2024 * | 596M 82.54M | Sales 2025 * | 827M 114M | Capitalization | 1.33B 184M |
---|---|---|---|---|---|
Net income 2024 * | -297M -41.12M | Net income 2025 * | -122M -16.89M | EV / Sales 2024 * | 2.23 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.61 x |
P/E ratio 2024 * |
-2.21
x | P/E ratio 2025 * |
-6.48
x | Employees | 773 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 18.57% |
1 day | +2.93% | ||
1 week | +0.81% | ||
Current month | +38.91% | ||
1 month | +4.48% | ||
3 months | +142.05% | ||
6 months | +54.85% | ||
Current year | +91.37% |
Managers | Title | Age | Since |
---|---|---|---|
Hui Shao
CEO | Chief Executive Officer | 55 | 20-12-30 |
Chun Yuan Wu
DFI | Director of Finance/CFO | 46 | 20-12-30 |
Zenaida Mojares
CTO | Chief Tech/Sci/R&D Officer | 65 | 21-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Viren Mehta
BRD | Director/Board Member | 74 | - |
Hui Shao
CEO | Chief Executive Officer | 55 | 20-12-30 |
Ajit Shetty
CHM | Chairman | 77 | 20-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 0.9779 | +2.93% | 62,327 |
24-05-16 | 0.9501 | -7.76% | 44,089 |
24-05-15 | 1.03 | +4.24% | 73,750 |
24-05-14 | 0.9881 | +9.78% | 74,605 |
24-05-13 | 0.9001 | -7.21% | 109,165 |
Delayed Quote Nasdaq, May 17, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+91.37% | 179M | |
-2.32% | 92.59B | |
+3.68% | 41.43B | |
-10.90% | 33.49B | |
-19.56% | 14.62B | |
-9.06% | 12.77B | |
-11.34% | 11.58B | |
-43.53% | 11.35B | |
+3.75% | 8.97B | |
-6.32% | 8.3B |
- Stock Market
- Equities
- YS Stock